150375-75-0|Relcovaptan|(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide|-范德生物科技公司

Relcovaptan

NMR下载 COA and HPLC MSDS下载
names：
(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide
CAS号：
150375-75-0
MDL Number：
MF(分子式)： C28H27Cl2N3O7S MW(分子量)： 620.49
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK18537-5mg	5mg	>98%	¥ 4200.00	¥ 4200.00		2 Weeks	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide
英文别名	Relcovaptan; SR-49059; SR 49059; SR49059;
CAS号	150375-75-0
SMILES	O=C([C@H]1N(C([C@@H]2N(S(=O)(C3=CC=C(OC)C(OC)=C3)=O)C4=C(C=C(Cl)C=C4)[C@@]2(C5=CC=CC=C5Cl)O)=O)CCC1)N
Inchi	InChI=1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1
InchiKey	CEBYCSRFKCEUSW-NAYZPBBASA-N
分子式 Formula	C28H27Cl2N3O7S
分子量 Molecular Weight	620.49
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Relcovaptan(CAS:150375-75-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Relcovaptan is a selective non-peptide vasopressin V1A receptor antagonist.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Kubo A, Shinoda M, Katagiri A, Takeda M, Suzuki T, Asaka J, Yeomans DC, Iwata K. Oxytocin alleviates orofacial mechanical hypersensitivity associated with infraorbital nerve injury through vasopressin-1A receptors of the rat trigeminal ganglia. Pain. 2017 Apr;158(4):649-659. doi: 10.1097/j.pain.0000000000000808. PubMed PMID: 28072605.

[2]Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V(1A) receptors. Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E127-E135. doi: 10.1152/ajpendo.00269.2016. Epub 2016 Dec 20. PubMed PMID: 27998960.

[3] Cragg B, Ji G, Neugebauer V. Differential contributions of vasopressin V1A and oxytocin receptors in the amygdala to pain-related behaviors in rats. Mol Pain. 2016 Nov 11;12. pii: 1744806916676491. Print 2016. PubMed PMID: 27837170; PubMed Central PMCID: PMC5117246.

[4] Hicks C, Ramos L, Dampney B, Baracz SJ, McGregor IS, Hunt GE. Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059. Brain Res Bull. 2016 Oct;127:208-218. doi: 10.1016/j.brainresbull.2016.10.005. Epub 2016 Oct 8. PubMed PMID: 27725169.

[5] Ramos L, Hicks C, Caminer A, Couto K, Narlawar R, Kassiou M, McGregor IS. MDMA ('Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacol Biochem Behav. 2016 Nov - Dec;150-15[5]115-123. doi: 10.1016/j.pbb.2016.10.002. Epub 2016 Oct 7. PubMed PMID: 27725273.

6: Javadian N, Rahimi N, Javadi-Paydar M, Doustimotlagh AH, Dehpour AR. The modulatory effect of nitric oxide in pro- and anti-convulsive effects of vasopressin in PTZ-induced seizures threshold in mice. Epilepsy Res. 2016 Oct;12

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开